IGG Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IGGGF research report →
Price Chart
About the company
IGG Inc operates as an investment holding company primarily focused on the creation and management of mobile and online games. Its market reach is truly global, extending across Asia, North America, Europe, and other international territories. The company provides a diverse array of digital entertainment, including titles for mobile devices, web browsers, personal computers, and dedicated client software, all accessible in 23 different languages.
- CEO
- Zongjian Cai
- IPO
- 2015
- Employees
- 2,321
- HQ
- Singapore, CE, SG
Get TickerSpark's AI analysis on IGGGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $478.22M
- P/E
- 6.55
- Fwd P/E
- 0.87
- PEG
- 3.27
- P/S
- 0.66
- P/B
- 1.17
- EV/EBITDA
- 2.36
- Div Yield
- 20.45%
- Gross Margin
- 84.07%
- Op Margin
- 13.23%
- Net Margin
- 10.04%
- ROE
- 17.09%
- ROIC
- 17.90%
Latest fiscal year · YoY change
- Revenue
- $5.50B-4.2%
- Gross Profit
- $4.56B-1.1%
- Op Income
- $630.26M
- Net Income
- $580.36M-0.1%
- EPS
- $0.51+0.0%
- OCF Growth
- -39.4%
- FCF Growth
- -47.0%
- 52W High
- $0.67
- 52W Low
- $0.35
- 50D MA
- $0.40
- 200D MA
- $0.45
- Beta
- 1.02
- RSI (14)
- 80
- Avg Volume
- 42
No earnings-call transcripts are available for IGGGF yet.
- Free Float
- 61.6%
- Shares Outstanding
- 1.12B
- Float Shares
- 688.94M
Held by 1 ETFs
Biggest fund positions in IGGGF by dollar value.
Our IGGGF coverage
Recent articles, reports, and earnings notes.
No research on IGGGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IGGGF report →UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
prnewswire.com · Apr 3
Ticking Time Bombs: 3 Gaming Stocks to Dump Before the Damage Is Done
investorplace.com · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.